Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics
Ландшафт тестирования дефицита гомологичной рекомбинации (HRD): клинические применения и техническая валидация для рутинной диагностики
2025-02-21
SCID: 54.1/3t7grzt3
Discuss with AI
BRCA mutation testingHRD testing methodologiesPARP inhibitors (PARPi)genomic scarshomologous recombination deficiency (HRD)
Figures from the paper
Abstract (AI)
The use of poly(ADP-ribose) polymerase inhibitors (PARPi) revolutionized the treatment of BRCA-mutated cancers. Identifying patients exhibiting homologous recombination deficiency (HRD) has been proved useful to predict PARPi efficacy. However, obtaining HRD status remains an arduous task due to its evolution over the time. This causes HRD status to become obsolete when obtained from genomic scars, rendering PARPi ineffective for these patients. Only two HRD tests are currently FDA-approved, both based on genomic scars detection and BRCA mutations testing. Nevertheless, new technologies for obtaining an increasingly reliable HRD status continue to evolve. Application of these tests in clinical practice is an additional challenge due to the need for lower costs and shorter time to results delay.In this review, we describe the currently available methods for HRD testing, including the methodologies and corresponding tests for assessing HRD status, and discuss the clinical routine application of these tests and their technical validation.
Key Findings
1
Clinical implementation of HRD testing faces challenges of cost reduction and shorter turnaround times, requiring technical validation for routine diagnostics.
2
HRD status can evolve over time, making genomic-scar-based HRD assessments potentially obsolete and leading to ineffective PARPi treatment.
3
New technologies for more reliable HRD assessment are emerging, aiming to overcome limitations of genomic-scar-based tests.
4
Only two FDA-approved HRD tests exist, both relying on genomic scar detection and BRCA mutation testing.
5
PARP inhibitors (PARPi) revolutionized treatment of BRCA-mutated cancers and HRD identification predicts PARPi efficacy.
Research Object
Methods and tests for assessing homologous recombination deficiency (HRD) status
Research Subject
Clinical applications, routine diagnostic implementation, and technical validation (performance, reliability, cost and turnaround time) of HRD testing methods
Publication Details
Publication Date
2025-02-21
Journal
Publisher
ISSN
Cited by
44
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai5
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer2012
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers2014
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study2023
Assessing homologous recombination deficiency (HRD) in ovarian cancer: Optimizing concordance of the regulatory-approved companion diagnostic and a next-generation sequencing (NGS) assay kit.2022
The repertoire of mutational signatures in human cancer2020
Cited by2
Molecular diagnostics in clinical oncology: an overview2025
Сучасні підходи до лікування поширеного раку яєчників у 1-й лінії терапії (дослідження PAOLA-1) та рецидивного раку яєчника незалежно від наявності мутацій BRCA, а також сучасні циторедуктивні підходи (за матеріалами конгресу ESGO 2025)2025